VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
56 hedge funds and large institutions have $49.4M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 20 increasing their positions, 4 reducing their positions, and 12 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 4
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
30% more funds holding
Funds holding: 43 → 56 (+13)
46% less capital invested
Capital invested by funds: $92M → $49.4M (-$42.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.29M |
| 2 |
PA
Perceptive Advisors
New York
|
+$3.61M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.43M |
| 4 |
Goldman Sachs
New York
|
+$993K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$766K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$9.84M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$8.83M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.46M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.59M |
| 5 |
Millennium Management
New York
|
-$1.47M |
VBIV Hedge Fund Activity: Q2 2019 in Review
56 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q2 2019, worth a combined $49.4M — down 46% from $92M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VBIV positions and 12 closed out — a net gain of 13 holders — while 20 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $7.29M. The largest seller was Menora Mivtachim Holdings, exiting entirely with an estimated $9.84M sold.
- 56 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q2 2019, up from 43 in Q1 2019.
- Funds reported $49.4M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q2 2019, down 46% quarter-over-quarter.
- 25 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q2 2019 and 12 closed out, a net change of +13 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q2 2019 was BlackRock, an estimated $7.29M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q2 2019 was Menora Mivtachim Holdings, an estimated $9.84M sold.
Based on aggregated 13F filings for Q2 2019.